Share

    


Home / Search Results

Search Results

You searched for:

As CAR T-cell therapies provide new treatment options for patients with certain hematologic malignancies, it is important that more cancer centers and programs deliver them.
ACCC in partnership with HealthTree Foundation for Acute Myeloid Leukemia, has launched an education program to explore the current barriers in care coordination and therapy options for patients with AML who are not eligible for transplant.
With data already demonstrating the role of MRD for CLL response assessment and prognosis, cancer programs should prepare themselves for implementation of MRD testing for appropriate patients.